Aktivax, Inc.
Dba Aktivax
CAGE Code: 5D8W7
NCAGE Code: 5D8W7
Status: Active
Type: Manufacturer
Dun & Bradstreet (DUNS): 829818116
Summary
Aktivax, Inc., Dba Aktivax is an Active Manufacturer with the Cage Code 5D8W7 and is tracked by Dun & Bradstreet under DUNS Number 829818116..
Address
100 Technology Dr Ste 200A
Broomfield CO 80021-3692
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Sturgeon Electric Company, Inc. Phoenix Analytical Laboratories Inc Checkers Industrial Products, Llc Intelagard Inc Rf Micro Devices, Inc. Ellis Construction Specialists Ltd Wolven Engineering, Llc Flatiron Constructors, Inc. Mwh - Mcalvain, Joint Venture Rocky Flats Technical Associates Inc Photonics Research Inc Revolutionary Enterprises Llc Corporate Express Inc Envirotech Services Inc. Dba Enviro Computerized Pricing Systems Arapahoe Roofing And Sheet Metal Inc Altec Air, Llc Vixel Corp Rieckhoff Inc Rkm Construction Co Inc
Frequently Asked Questions (FAQ) for CAGE 5D8W7
- What is CAGE Code 5D8W7?
- 5D8W7 is the unique identifier used by NATO Organizations to reference the physical entity known as Aktivax, Inc. Dba Aktivax located at 100 Technology Dr Ste 200A, Broomfield CO 80021-3692, United States.
- Who is CAGE Code 5D8W7?
- 5D8W7 refers to Aktivax, Inc. Dba Aktivax located at 100 Technology Dr Ste 200A, Broomfield CO 80021-3692, United States.
- Where is CAGE Code 5D8W7 Located?
- CAGE Code 5D8W7 is located in Broomfield, CO, USA.
Contracting History for CAGE 5D8W7 Most Recent 25 Records
- 75A50122C00082
- This Acquisition Will Allow Barda To Invest Project Bioshield Funds For Late-Stage Clinical Development, Regulatory Approval For 2-Pam Autoinjectors (As A Drug/Device Combination Product) To Treat Organophosphate (Op) Poisoning, Including Nerve Agent
- 28 Sep 2022
- This Acquisition Will Allow Barda To Invest Project Bioshield Funds For Late-Stage Clinical Development, Regulatory Approval For 2-Pam Autoinjectors (As A Drug/Device Combination Product) To Treat Organophosphate (Op) Poisoning, Including Nerve Agent
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $45,323,792.00
- Department Of Health And Human Services (Hhs)
- 75A50122C00082
- This Acquisition Will Allow Barda To Invest Project Bioshield Funds For Late-Stage Clinical Development, Regulatory Approval For 2-Pam Autoinjectors (As A Drug/Device Combination Product) To Treat Organophosphate (Op) Poisoning, Including Nerve Agent
- 14 Feb 2023
- This Acquisition Will Allow Barda To Invest Project Bioshield Funds For Late-Stage Clinical Development, Regulatory Approval For 2-Pam Autoinjectors (As A Drug/Device Combination Product) To Treat Organophosphate (Op) Poisoning, Including Nerve Agent
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $45,323,792.00
- Department Of Health And Human Services (Hhs)
- W911QY17C0045
- Atropine/2-Pam And Naloxone/Nalmefene
- 10 Feb 2020
- Atropine/2-Pam And Naloxone/Nalmefene
- W6qk Acc-Apg Natick
- Department Of Defense (Dod)
- $2,647,665.96
- Department Of Defense (Dod)
- 75A50118D00014
- Incorporate Assignment Of Claims To Live Oak Bank Company
- 29 Jun 2022
- Incorporate Assignment Of Claims To Live Oak Bank Company
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $38,985,161.00
- Department Of Health And Human Services (Hhs)
- W911QY17C0045
- Igf::Ot::Igf
- 8 Mar 2017
- Igf::Ot::Igf
- W6qk Acc-Apg Natick
- Department Of Defense (Dod)
- $2,647,665.96
- Department Of Defense (Dod)
- 75A50118D00014
- Igf::Ot::Igf Arai Auto-Injector Platform
- 22 Jun 2018
- Igf::Ot::Igf Arai Auto-Injector Platform
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $15,087,844.00
- Department Of Health And Human Services (Hhs)
- W911QY17C0045
- Diazepam Studies
- 19 Nov 2019
- Diazepam Studies
- W6qk Acc-Apg Natick
- Department Of Defense (Dod)
- $2,647,665.96
- Department Of Defense (Dod)
- W911QY17C0045
- Additional Scope Work Order 1&2
- 28 Sep 2018
- Additional Scope Work Order 1&2
- W6qk Acc-Apg Natick
- Department Of Defense (Dod)
- $2,320,847.96
- Department Of Defense (Dod)
- 75A50118D00014
- Incorporate Assignment Of Claims To Live Oak Bank Company
- 8 Dec 2021
- Incorporate Assignment Of Claims To Live Oak Bank Company
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $38,066,853.00
- Department Of Health And Human Services (Hhs)
- 75A50118D00014
- Arai Auto-Injector Platform
- 14 Feb 2020
- Arai Auto-Injector Platform
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $16,641,246.00
- Department Of Health And Human Services (Hhs)
- 75A50118D00014
- Arai Auto-Injector Platform
- 21 Mar 2020
- Arai Auto-Injector Platform
- Office Of Acq&Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $32,812,241.00
- Department Of Health And Human Services (Hhs)
- 75A50118D00014
- Incorporate Assignment Of Claims To Live Oak Bank Company
- 22 Aug 2022
- Incorporate Assignment Of Claims To Live Oak Bank Company
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $39,978,127.00
- Department Of Health And Human Services (Hhs)
- 75A50118D00014
- Arai Auto-Injector Platform
- 13 Nov 2019
- Arai Auto-Injector Platform
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $15,877,934.00
- Department Of Health And Human Services (Hhs)
- W911QY17C0045
- Monthly Status Reports
- 7 Mar 2018
- Monthly Status Reports
- W6qk Acc-Apg Natick
- Department Of Defense (Dod)
- $999,847.96
- Department Of Defense (Dod)
- W911QY17C0045
- Igf::Ot::Igf 60 Day No Cost Extension
- 9 May 2018
- Igf::Ot::Igf 60 Day No Cost Extension
- W6qk Acc-Apg Natick
- Department Of Defense (Dod)
- $999,847.96
- Department Of Defense (Dod)
- W911QY17C0045
- Atropine/2-Pam And Naloxone/Nalmefene - No Cost Extension To 31 Oct 2020
- 15 Apr 2020
- Atropine/2-Pam And Naloxone/Nalmefene - No Cost Extension To 31 Oct 2020
- W6qk Acc-Apg Natick
- Department Of Defense (Dod)
- $2,647,665.96
- Department Of Defense (Dod)
- 75A50118D00014
- Incorporate By Executive Order 14042 - Far Deviation Clause 52.223-99
- 30 Nov 2021
- Incorporate By Executive Order 14042 - Far Deviation Clause 52.223-99
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $38,066,853.00
- Department Of Health And Human Services (Hhs)
- 75A50118D00014
- Provide A No-Cost Extension Of Option 1/Clin0002 Thru 9/30/2021
- 24 Sep 2021
- Provide A No-Cost Extension Of Option 1/Clin0002 Thru 9/30/2021
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $32,812,241.00
- Department Of Health And Human Services (Hhs)
- W911QY17C0045
- Atropine/2-Pam And Naloxone/Nalmefene
- 18 Sep 2019
- Atropine/2-Pam And Naloxone/Nalmefene
- W6qk Acc-Apg Natick
- Department Of Defense (Dod)
- $2,647,665.96
- Department Of Defense (Dod)
- W911QY17C0045
- Monthly Status Reports
- 4 Sep 2018
- Monthly Status Reports
- W6qk Acc-Apg Natick
- Department Of Defense (Dod)
- $2,320,847.96
- Department Of Defense (Dod)
- W911QY17C0045
- Atropine/2-Pam And Naloxone/Nalmefene
- 9 Jan 2019
- Atropine/2-Pam And Naloxone/Nalmefene
- W6qk Acc-Apg Natick
- Department Of Defense (Dod)
- $2,462,758.96
- Department Of Defense (Dod)
- 75A50118D00014
- Provide Additional Funding For Option 1/Clin0002 & Extend Pop
- 30 Sep 2021
- Provide Additional Funding For Option 1/Clin0002 & Extend Pop
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $38,066,853.00
- Department Of Health And Human Services (Hhs)
- W911QY17C0045
- Atropine/2-Pam And Naloxone/Nalmefene
- 10 Jun 2019
- Atropine/2-Pam And Naloxone/Nalmefene
- W6qk Acc-Apg Natick
- Department Of Defense (Dod)
- $2,462,758.96
- Department Of Defense (Dod)
- 75A50118D00014
- Administrative Action: No Cost Extension
- 1 Sep 2021
- Administrative Action: No Cost Extension
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $32,812,241.00
- Department Of Health And Human Services (Hhs)